Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model

Antiviral Research

Volumn 87, Issue 3, 2010, Pages 361-366

  Hurt, Aeron C ^a,b   Lowther, Sue ^c   Middleton, Deborah ^c   Barr, Ian G ^a,b  

^a WHO COLLABORATING CENTRE FOR REFERENCE AND RESEARCH ON INFLUENZA   (Australia)

^b UNIVERSITY OF BALLARAT   (Australia)

^c CSIRO   (Australia)

Author keywords

Ferrets; Highly pathogenic A(H5N1) influenza virus; NA inhibitors; Neuraminidase inhibitors; Oseltamivir; Q136; Resistance; Zanamivir

Indexed keywords

OSELTAMIVIR; VIRUS SIALIDASE; ZANAMIVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; FERRET; IC 50; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SEROCONVERSION; SURVIVAL TIME; VIRUS SHEDDING; VIRUS VIRULENCE;

ANIMALIA; INFLUENZA A VIRUS; MUSTELA; ORTHOMYXOVIRIDAE;

EID: 77955842998     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.06.009     Document Type: Article

References (25)

1. Abdel-Ghafar A.N., Chotpitayasunondh T., Gao Z., Hayden F.G., Nguyen D.H., de Jong M.D., Naghdaliyev A., Peiris J.S., Shindo N., Soeroso S., Uyeki T.M. Update on avian influenza A (H5N1) virus infection in humans. N. Engl. J. Med. 2008, 358:261-273.
2. Boltz D.A., Rehg J.E., McClaren J., Webster R.G., Govorkova E.A. Oseltamivir prophylactic regimens prevent H5N1 influenza morbidity and mortality in a ferret model. J. Infect. Dis. 2008, 197:1315-1323.
3. Cass L.M., Brown J., Pickford M., Fayinka S., Newman S.P., Johansson C.J., Bye A. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin. Pharmacokinet. 1999, 36(Suppl. 1):21-31.
4. Cass L.M., Efthymiopoulos C., Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin. Pharmacokinet. 1999, 36(Suppl. 1):1-11.
5. de Jong M.D., Hien T.T. Avian influenza A (H5N1). J. Clin. Virol. 2006, 35:2-13.
6. de Jong M.D., Simmons C.P., Thanh T.T., Hien V.M., Smith G.J., Chau T.N., Hoang D.M., Chau N.V., Khanh T.H., Dong V.C., Qui P.T., Cam B.V., Ha do Q., Guan Y., Peiris J.S., Chinh N.T., Hien T.T., Farrar J. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 2006, 12:1203-1207.
7. de Jong M.D., Tran T.T., Truong H.K., Vo M.H., Smith G.J., Nguyen V.C., Bach V.C., Phan T.Q., Do Q.H., Guan Y., Peiris J.S., Tran T.H., Farrar J. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 2005, 353:2667-2672.
8. de Jong M., Bach V.C., Phan T.Q., Vo M.H., Tran T.T., Nguyen B.H., Beld M., Le T.P., Truong H.K., Nguyen V.V., Tran T.H., Do Q.H., Farrar J. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N. Engl. J. Med. 2005, 352:686-691.
9. Govorkova E.A., Ilyushina N.A., Boltz D.A., Douglas A., Yilmaz N., Webster R.G. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob. Agents Chemother. 2007, 51:1414-1424.
10. He G., Massarella J., Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin. Pharmacokinet. 1999, 37:471-484.
11. Hurt A.C., Barr I.G., Hartel G., Hampson A.W. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. Antiviral Res. 2004, 62:37-45.
12. Hurt A.C., Ho H.T., Barr I. Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors. Expert Rev. Anti Infect. Ther. 2006, 4:795-805.
13. Hurt A.C., Holien J.K., Barr I.G. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob. Agents Chemother. 2009, 53:4433-4440.
14. Hurt A.C., Holien J.K., Parker M.W., Barr I.G. Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses. Drugs 2009, 69:2523-2531.
15. Hurt A.C., Holien J.K., Parker M., Kelso A., Barr I.G. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J. Virol. 2009, 83:10366-10373.
16. Le Q.M., Kiso M., Someya K., Sakai Y.T., Nguyen T.H., Nguyen K.H., Pham N.D., Ngyen H.H., Yamada S., Muramoto Y., Horimoto T., Takada A., Goto H., Suzuki T., Suzuki Y., Kawaoka Y. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005, 437:1108.
17. McKimm-Breschkin J.L. Resistance of influenza viruses to neuraminidase inhibitors-a review. Antiviral Res. 2000, 47:1-17.
18. Okomo-Adhiambo M., Nguyen H.T., Sleeman K., Sheu T.G., Deyde V.M., Garten R.J., Xu X., Shaw M.W., Klimov A.I., Gubareva L.V. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. Antiviral Res. 2010, 85:381-388.
19. Sheu T.G., Deyde V.M., Okomo-Adhiambo M., Garten R.J., Xu X., Bright R.A., Butler E.N., Wallis T.R., Klimov A.I., Gubareva L.V. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 2008, 52:3284-3292.
20. Stittelaar K.J., Tisdale M., van Amerongen G., van Lavieren R.F., Pistoor F., Simon J., Osterhaus A.D. Evaluation of intravenous zanamivir against experimental influenza A (H5N1) virus infection in cynomolgus macaques. Antiviral Res. 2008, 80:225-228.
21. ®) and its potential for use in the event of an influenza pandemic. J. Antimicrob. Chemother. 2005, 55(Suppl. 1):i7-i8.
22. Webster R.G., Govorkova E.A. H5N1 influenza-continuing evolution and spread. N. Engl. J. Med. 2006, 355:2174-2177.
23. White N.J., Webster R.G., Govorkova E.A., Uyeki T.M. What is the optimal therapy for patients with H5N1 influenza?. PLoS Med. 2009, 6:e1000091.
24. WHO, 2009. , website (accessed 08.10.09). http://www.who.int/csr/disease/avian_influenza/country/cases_table_2009_09_24/en/index.html.
25. Yen H.L., Monto A.S., Webster R.G., Govorkova E.A. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J. Infect. Dis. 2005, 192:665-672.